We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+29.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.47B
AUM Growth
+$451M
(+5%)
Cap. Flow
+$1.13B
Cap. Flow
% of AUM
11.96%
Top 10 Holdings %
Top 10 Hldgs %
21.59%
Holding
903
New
107
Increased
255
Reduced
393
Closed
103
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$51.9M |
| 2 |
Merck
MRK
|
+$50.9M |
| 3 |
Danaher
DHR
|
+$45.3M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$37.8M |
| 5 |
JD.com
JD
|
+$37.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$103M |
| 2 |
Alibaba
BABA
|
+$98.6M |
| 3 |
Salesforce
CRM
|
+$62.5M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$59.4M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$48.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.61% |
| 2 | Technology | 20.94% |
| 3 | Consumer Discretionary | 8.9% |
| 4 | Financials | 8.59% |
| 5 | Communication Services | 7.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Huntington Ingalls Industries
HII
$11.8B
| $5.63M | 0.06% |
32,260
+26,920
| +504% | +$5M |
|
302
Toronto Dominion Bank
TD
$199B
| $5.59M | 0.06% |
125,740
-50,611
| -29% | -$2.15M |
|
303
Ormat Technologies
ORA
$6.05B
| $5.59M | 0.06% |
+88,052
| New | +$5.76M |
|
304
Cardinal Health
CAH
$54.5B
| $5.59M | 0.06% |
107,098
+68,724
| +179% | +$3.54M |
|
305
Blackrock
BLK
$170B
| $5.55M | 0.06% |
10,195
-550
| -5% | -$278K |
|
306
Arcus Biosciences
RCUS
$3.4B
| $5.51M | 0.06% |
+222,942
| New | +$6.02M |
|
307
Roper Technologies
ROP
$38.7B
| $5.5M | 0.06% |
14,174
-2,418
| -15% | -$866K |
|
308
Jones Lang LaSalle
JLL
$15.9B
| $5.47M | 0.06% |
52,883
-41,764
| -44% | -$4.3M |
|
309
Pfizer
PFE
$144B
| $5.46M | 0.06% |
175,984
-360,314
| -67% | -$12.2M |
|
310
Veracyte
VCYT
$4.44B
| $5.41M | 0.06% |
209,015
+45,591
| +28% | +$1.14M |
|
311
Akamai
AKAM
$16.3B
| $5.36M | 0.06% |
50,014
-19,887
| -28% | -$2M |
|
312
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$4.95B
| $5.36M | 0.06% |
188,152
+93,690
| +99% | +$2.56M |
|
|
TCDA
313
DELISTED
Tricida, Inc. Common Stock
TCDA
| $5.26M | 0.06% |
191,500
+7,500
| +4% | +$204K |
|
314
Restaurant Brands International
QSR
$26B
| $5.17M | 0.05% |
95,364
+90,254
| +1,766% | +$4.55M |
|
|
MRSH
315
Marsh
MRSH
$91.7B
| $5.17M | 0.05% |
48,108
-8,003
| -14% | -$810K |
|
316
Syndax Pharmaceuticals
SNDX
$1.74B
| $5.15M | 0.05% |
+347,458
| New | +$5.29M |
|
|
CETV
317
DELISTED
Central European Media Enterprises Ltd
CETV
| $5.13M | 0.05% |
1,450,357
-1,017,644
| -41% | -$3.76M |
|
318
Baker Hughes
BKR
$58B
| $5.12M | 0.05% |
332,726
-25,968
| -7% | -$380K |
|
319
Parker-Hannifin
PH
$125B
| $5.12M | 0.05% |
27,916
-10,576
| -27% | -$1.71M |
|
320
Boston Properties
BXP
$11.2B
| $5.11M | 0.05% |
56,499
+41,165
| +268% | +$3.74M |
|
|
SAGE
321
DELISTED
Sage Therapeutics
SAGE
| – | – |
-149,300
| Closed | -$5.42M |
|
322
Aprea Therapeutics
APRE
$7.6M
| $5.07M | 0.05% |
+6,539
| New | +$4.29M |
|
323
United Rentals
URI
$67.9B
| $5.01M | 0.05% |
33,598
+26,234
| +356% | +$3.33M |
|
324
Genmab
GMAB
$17.8B
| $4.96M | 0.05% |
146,430
-46,432
| -24% | -$1.27M |
|
325
Freeport-McMoran
FCX
$88.6B
| $4.96M | 0.05% |
+428,258
| New | +$3.93M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2020 Portfolio in Review
As of Q2 2020, Candriam SCA held 903 positions worth $9.47B, up 5% from $9.02B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $1.13B of net new capital in Q2 2020, opening 107 new positions and adding to 255 existing holdings. Its largest new stake was JD.com: 744,410 shares worth $44.8M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $103M trimmed.
- Candriam SCA's largest Q2 2020 buy was JD.com: 744,410 shares worth $44.8M.
- Candriam SCA added most to Blueprint Medicines in Q2 2020, an estimated $51.9M increase.
- Candriam SCA's biggest Q2 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $103M.
- Candriam SCA fully exited Salesforce in Q2 2020, selling an estimated $62.5M.
- Candriam SCA's ten largest holdings make up 22% of its $9.47B portfolio in Q2 2020.
- Candriam SCA opened 107 new positions and closed 103 in Q2 2020.
- Candriam SCA's portfolio value rose 5% quarter-over-quarter to $9.47B.
Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.